Overview

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

Status:
Terminated
Trial end date:
2018-05-22
Target enrollment:
Participant gender:
Summary
Subjects stable on L-Dopa and oral ropinirole will have their ropinirole replaced with the Ropinirole Implant(s). The Ropinirole Implant was designed using the ProNeura™ implant technology where the implant is inserted under the skin. This study will measure how much ropinirole is released in the blood during 3 months of treatment, and evaluate the side effects of this new formulation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Titan Pharmaceuticals
Treatments:
Dopamine
Ropinirole